-+ 0.00%
-+ 0.00%
-+ 0.00%
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
Share
Listen to the news

- For patients with second-line (2L) metastatic pancreatic cancer, today’s FDA approval of a new treatment is an important milestone – 

- For patients with first-line (1L) metastatic pancreatic cancer, Immuneering’s atebimetinib is being evaluated in a global randomized Phase 3 trial, MAPKeeper 301 –

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending